CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
| 3.08 | |
| 3.16 | |
| - | |
| 3.16 | |
| 3.08 | |
| 1.805-4.06 | |
| 1 190 M | |
| 133 M | |
| 749 M | |
| 0.52 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
By Brenda Goh and Miyoung Kim SHANGHAI, Aug 31 (Reuters) - China's CanSino Biologics , which recently announced a contract manufacturing deal to support AstraZenca's messenger RNA (mRNA) technology v...
Drugmaker says it is working on new technologies to develop vaccines for infectious diseases where there is ‘high unmet need’ Continue reading
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
